Venus Remedies posts 89% profit jump and names new board members
The company reported a standalone net profit of ₹99.3 crore for FY26. It also appointed Saransh Chaudhary as a whole-time director.
— 2 earlier stories on Venus Remedies Ltd. →What's new
- Standalone net profit rose 89% to ₹99.3 crore on revenue of ₹768.7 crore.
- Consolidated net profit grew 127% to ₹102.8 crore for the year.
- Saransh Chaudhary joins as a whole-time director; Dr. Gurminder Singh Bedi joins as an independent director.
Why this matters
The financial results confirm the company's growth. The board changes signal a focus on long-term governance and succession planning.
What we're watching
- The impact of the new leadership on future revenue growth.
- Shareholder reaction to the ₹10 per share dividend payout.
- Integration of the updated memorandum and articles of association.
The full read
Venus Remedies closed FY26 with strong growth, reporting a standalone net profit of ₹99.3 crore (an 89% increase) on revenue of ₹768.7 crore. Consolidated performance was even stronger, with net profit climbing 127% to ₹102.8 crore. Alongside these audited figures, the board recommended a final dividend of ₹10 per share. The company is also reshaping its leadership team. Saransh Chaudhary, formerly the company's Global Critical Care president, moves into a five-year term as a whole-time director. Orthopaedic surgeon Dr. Gurminder Singh Bedi joins the board as an independent director. The board also re-appointed Dr. Manu Chaudhary and Dr. Savita Gupta to their roles. To round out the administrative updates, Venus Remedies adopted an updated memorandum and articles of association to ensure compliance with the 2013 Companies Act. These changes reflect a clear effort to modernize the company's governance structure as it scales.
Questions answered
- What were the key financial results for Venus Remedies in FY26?
- The company reported a standalone net profit of ₹99.3 crore, up 89%, and a consolidated net profit of ₹102.8 crore, up 127%. Revenue for the year stood at ₹768.7 crore.
- What dividend did the board recommend?
- The board recommended a final dividend of ₹10 per share.
- Who are the new appointees to the board?
- Saransh Chaudhary, previously the Global Critical Care president, was appointed as a whole-time director for five years. Dr. Gurminder Singh Bedi, an orthopaedic surgeon, joined as an independent director.
- Were there any other board changes?
- The board also approved the re-appointments of Dr. Manu Chaudhary and Dr. Savita Gupta.
Story so far
All notes on VENUSREM →- 26 May 2026 · 10:07 PM IST Venus Remedies posts 89% profit jump and names new board members
- today Venus Remedies reports audited results and declares dividend
- today Venus Remedies profit jumps 89% as annual revenue hits ₹768.7 cr